Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN88 · 3 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | dose 1 vs. placebo |
| 2 | ACTIVE_COMPARATOR | dose 2 vs. placebo |
| 3 | ACTIVE_COMPARATOR | dose 3 vs. placebo |
| 4 | ACTIVE_COMPARATOR | dose 4 vs. placebo |
| 5 | ACTIVE_COMPARATOR | dose 5 vs. placebo |
| 6 | ACTIVE_COMPARATOR | dose 6 vs. placebo |
| Dose 1 | EXPERIMENTAL | Active dose |
| Dose 2 | EXPERIMENTAL | Active dose |
| Dose 3 | EXPERIMENTAL | Active 3 |
| Dose 4 | PLACEBO_COMPARATOR | Placebo dose |
| Name | Type | Description |
|---|---|---|
| REGN88 | BIOLOGICAL | This study will be conducted in 3 parts, and will include a total of 6 dose cohorts. Part B will not begin until the safety of Part A has been assessed. Part C will begin when enrollment into Part B is complete. |
| Placebo | OTHER | Placebo to match REGN88 administration |
Inclusion Criteria: * Patients with an established diagnosis of Rheumatoid Arthritis * Patients currently treated with concomitant methotrexate for at least 12 weeks, with a stable dose for at least 6 weeks Exclusion Criteria: * Persistent chronic or current active infections * Patients who have ...
Top 20 of 28 competitors
REGN88 is an investigational small molecule being developed by Regeneron Pharmaceuticals for the treatment of Rheumatoid Arthritis. It is currently in Phase 1 clinical development, meaning it has not yet been approved by the FDA. The drug is being studied for its safety and tolerability in patients with this condition.
REGN88 is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol REGN. The drug is currently in Phase 1 clinical trials for Rheumatoid Arthritis, and it is an investigational small molecule therapy.
REGN88 is currently in Phase 1 clinical development. It has completed three Phase 1 trials, all of which were placebo-controlled and double-blinded, with a total enrollment of 107 participants. The drug is still investigational and has not been approved for any use.
REGN88 has completed three Phase 1 clinical trials for Rheumatoid Arthritis: NCT01011959, a multiple-dose safety study in the United States with 60 participants; NCT01026519, a safety and tolerability study in Russia with 32 participants; and NCT01055899, a single-dose safety study in the United States with 15 participants.
Yes, REGN88 is also known as SAR153191. This alternative name appears in the titles of its clinical trials, such as NCT01011959, which refers to REGN88(SAR153191). Both names refer to the same investigational drug being developed for Rheumatoid Arthritis.